Sodium Bicarbonate in Cardiac Surgery Study (Bic-MC)

This study has been terminated.
Sponsor:
Information provided by (Responsible Party):
Rinaldo Bellomo, Austin Health
ClinicalTrials.gov Identifier:
NCT00672334
First received: May 1, 2008
Last updated: July 31, 2012
Last verified: July 2012
  Purpose

With over one million operations a year, cardiac surgery with cardiopulmonary bypass is one of the most common major surgical procedures worldwide (1). Acute kidney injury is a common and serious postoperative complication of cardiopulmonary bypass and may affect 25% to 50% of patients (2-4). Acute kidney injury carries significant costs (4) and is independently associated with increased morbidity and mortality (2,3). Even minimal increments in plasma creatinine are associated with an increase in mortality (5,6).

Multiple causes of cardiopulmonary bypass-associated acute kidney injury have been proposed, including ischemia-reperfusion, generation of reactive oxygen species, hemolysis and activation of inflammatory pathways (7-10). COMT LL genotype appears to increase the risk of vasodilatory shock and AKI after cardiac surgery. To date, no simple, safe and effective intervention to prevent cardiopulmonary bypass-associated acute kidney injury in a broad patient population has been found (11-14).

Urinary acidity may enhance the generation and toxicity of reactive oxygen species induced by cardiopulmonary bypass (10,15). Activation of complement during cardiac surgery (16) may also participate in kidney injury. Urinary alkalinization may protect from kidney injury induced by oxidant substances, iron-mediated free radical pathways, complement activation and tubular hemoglobin cast formation (9,17,18). Of note, increasing urinary pH - in combination with N-acetylcysteine (19,20) or without (21) - has recently been reported to attenuate acute kidney injury in patients undergoing contrast-media infusion.

In a pilot double-blind, randomized controlled trial the investigators found sodium bicarbonate to be efficacious, safe, inexpensive and easy to administer. These findings now need to be confirmed or refuted by further clinical investigations in other geographic and institutional settings.

Accordingly, the investigators hypothesized that urinary alkalinization might protect kidney function in patients at increased risk of acute kidney injury undergoing cardiopulmonary bypass needs to be confirmed in an international multicenter, double-blind, randomized controlled trial of intravenous sodium bicarbonate.


Condition Intervention Phase
Cardiac Surgery
Cardiopulmonary Bypass
Drug: Sodium Bicarbonate
Drug: Sodium Chloride
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Multicenter, Randomized, Double Blind, Placebo Controlled Study of the Effect of Sodium Bicarbonate on Postoperative Renal Function in Patients Undergoing Elective Cardiopulmonary Bypass

Resource links provided by NLM:


Further study details as provided by Austin Health:

Primary Outcome Measures:
  • Proportion of patients developing an increase in serum creatinine > 25% or >44µmicromol/L from baseline to peak level after adjustment for relevant baseline characteristics [ Time Frame: within first two-five postoperative days. ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Proportion of patients developing an increase in serum creatinine greater than 50% from baseline to peak level after adjustment for relevant baseline characteristics [ Time Frame: within first two-five postoperative days ] [ Designated as safety issue: No ]
  • Proportion of patients developing an increase in serum creatinine greater than 100% from baseline to peak level after adjustment for relevant baseline characteristics [ Time Frame: within first two-five postoperative days ] [ Designated as safety issue: No ]
  • Change in serum creatinine from baseline to peak level after adjustment for relevant baseline characteristics [ Time Frame: within first two-five postoperative days ] [ Designated as safety issue: No ]
  • Proportion of patients developing any of the RIFLE criteria: R, I or F after adjustment for relevant baseline characteristics [ Time Frame: within first five postoperative days ] [ Designated as safety issue: No ]
  • Proportion of patients developing any of the AKI stages: 1, 2 or 3 (using network definition)after adjustment for relevant baseline characteristics [ Time Frame: within 48 hours postoperatively ] [ Designated as safety issue: No ]
  • Change in serum urea from baseline to peak [ Time Frame: within first two-five postoperative days ] [ Designated as safety issue: No ]
  • Change in NGAL from baseline to peak [ Time Frame: within first 24 postoperatively ] [ Designated as safety issue: No ]
  • Change in electrolyte status from baseline to peak [ Time Frame: within first 24-48hrs postoperatively ] [ Designated as safety issue: Yes ]
  • Requirement of renal replacement therapy [ Time Frame: within first postoperative days ] [ Designated as safety issue: No ]
  • Length of ventilation [ Time Frame: from commencement to end of intubation ] [ Designated as safety issue: No ]
  • Length of stay in Intensive care [ Time Frame: from admission to discharge from Intensive care ] [ Designated as safety issue: No ]
  • Length of stay in hospital [ Time Frame: from admission to discharge from hospital ] [ Designated as safety issue: No ]
  • Hospital-Mortality [ Time Frame: during hospital stay ] [ Designated as safety issue: No ]
  • 90-day mortality [ Time Frame: during 90 days postoperatively ] [ Designated as safety issue: No ]
  • COMT polymorphism [ Time Frame: sampling at induction of anesthesia ] [ Designated as safety issue: No ]

Enrollment: 350
Study Start Date: May 2008
Study Completion Date: January 2012
Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: 2
sodium chloride at 0.5 mmol/kg loading pre-induction and then at 0.2 mmol/kg/hr over 24 hours after induction until the next day
Drug: Sodium Chloride
In all patients body weight adjusted dose of study medication will be achieved by infusion of sodium chloride at a dose of 0.5 mmol/kg body weight (=bolus) diluted in 250 mL over 1 hour immediately after the induction of anesthesia, prior to the first surgical incision followed by continuous intravenous infusion of 0.2 mmol/kg/hr (=maintenance) diluted in 1000 mL 23 hours (total dose of 5 mmol/kg over 24 hours).
Other Name: hyeprtonic sodium chloride
Experimental: 1
The active intervention is loading (05. mmol/kg) pre-surgery and continuous infusion of bicarbonate at 0.2 mmol/kg/hr for 24 hours after induction
Drug: Sodium Bicarbonate
In all patients body weight adjusted dose of study medication will be achieved by infusion of sodium bicarbonate at a dose of 0.5 mmol/kg body weight (=bolus) diluted in 250 mL over 1 hour immediately after the induction of anesthesia, prior to the first surgical incision followed by continuous intravenous infusion of 0.2 mmol/kg/hr (=maintenance) diluted in 1000 mL 23 hours (total dose of 5 mmol/kg over 24 hours).
Other Name: Hypertonic bicarbonate

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Cardiac surgical patients in whom the use of cardiopulmonary bypass was planned and:
  • Written informed consent of patient
  • Age >18 years
  • And having at least one ore more of the following risk factors for postoperative AKI:

    • Age =/>70 years
    • Preoperative plasma creatinine >120 µmol/L New York Heart Association class III / IV or LVEF <35%
    • Insulin dependent diabetes mellitus
    • Valve surgery (with or without coronary artery bypass graft)
    • Redo cardiac surgery

Exclusion Criteria:

  • Cardiac surgical patients will not be considered eligible if:
  • An emergency operation is indicated (within 24 hours after hospital admission or on intra-aortic balloon pump) or
  • Pregnancy is confirmed or breastfeeding is present or
  • A renal allograft is present or
  • Preoperative acute renal failure within 6 weeks (acute rise in serum creatinine >50% from baseline) is present or
  • Pre-operative end stage renal disease (serum creatinine >300 µmol/L) is present or
  • Chronic moderate to high dose corticosteroid therapy (>10 mg/d prednisone or equivalent) is present
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00672334

Locations
Australia, Victoria
Austin Health
Melbourne, Victoria, Australia, 3084
Canada, Alberta
University of Alberta
Edmonton, Alberta, Canada, T6G 2B7
Germany
Charité University Medicine
Berlin, Germany, 13353
Ireland
University Clinic Dublin, School of Medicine and Medical Science
Dublin, Ireland
Sponsors and Collaborators
Austin Health
Investigators
Study Chair: Rinaldo Bellomo, MD, FRACP Austin Health, Melbourne, Australia
Principal Investigator: Michael Haase, MD Charité University Medicine Berlin, Germany
Principal Investigator: Sean M Bagshaw, MD University of Alberta, Edmonton, Canada
Principal Investigator: Patrick Murray, MD University Clinic Dublin, Dublin, Ireland
  More Information

No publications provided by Austin Health

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Rinaldo Bellomo, Director of ICU research, Austin Health
ClinicalTrials.gov Identifier: NCT00672334     History of Changes
Other Study ID Numbers: EudraCT 2007-002223-32
Study First Received: May 1, 2008
Last Updated: July 31, 2012
Health Authority: Australia: Department of Health and Ageing Therapeutic Goods Administration
Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by Austin Health:
Cardiac surgery
Cardiopulmonary bypass
Oxidative stress
Acute renal dysfunction
Sodium bicarbonate

ClinicalTrials.gov processed this record on September 30, 2014